AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05976152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dl-3-butylphthalide
Description: First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.
Study NCT05976152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-3-butylphthalide placebo
Description: First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.
Study NCT05976152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dl-3-butylphthalide placebo
Description: First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.
Study NCT05100771 — intervention group
Intervention type: OTHER
Intervention: Pediatric brain MRI
Description: Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
Study NCT04770558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Exergame
Description: The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
Study NCT04803864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
Study NCT05340478 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intensive Transdiagnostic Cognitive Behavioral Therapy
Description: cognitive behavioral treatment that addresses multiple anxiety problems simultaneously and delivered in a massed format over one weekend
Study NCT06162273 — intervention group
Intervention type: DEVICE
Intervention: IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company
Description: Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
Study NCT04981964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
Study NCT05340946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anaesthesia
Description: intraoperative general anaesthesia followed by postoperative IV patient analgesia
Study NCT05340946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anaesthesia
Description: patient received spinal followed by continuous ultrasound guided femoral never block.
Study NCT04625400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoscope
Description: Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
Study NCT04889248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training with Powerbreath IMT device.
Description: Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax.
Study NCT05982639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two lung ventilation
Description: The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.
Study NCT05982639 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: one lung ventilation
Description: In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
Study NCT05263570 — intervention group
Intervention type: DRUG
Intervention: Standard Therapy
Description: Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
Study NCT06005558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
Study NCT06005558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue low dose
Description: A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
Study NCT06005558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue high dose
Description: A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
Study NCT06380764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block
Description: The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance.
Study NCT06380764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral suboccipital intramuscular injection
Description: Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.
Study NCT06380764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.
Study NCT06380764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: Placebo drug
Study NCT06380764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
Study NCT05121298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upadacitinib 15mg/day
Description: Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
Study NCT06508528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a 12-week growth mindset intervention
Description: This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.
Study NCT06508528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospital mentoring
Description: The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
Study NCT05059704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Class Training
Description: Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
Study NCT05059704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Task specific training
Description: Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
Study NCT04689919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
Study NCT04689919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
Study NCT05729113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction technique
Description: Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
Study NCT02016495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium plus alpha-lipoic acid
Study NCT02016495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05448989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% atropine 5+3
Description: A method for myopia control using high-concentration atropine
Study NCT05448989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% atropine 5+3
Description: A method for myopia control using high-concentration atropine
Study NCT06552832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVEAT
Description: Brief manualized parent-child psychotherapy
Study NCT05494463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller blade
Description: After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
Study NCT05355935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.
Study NCT05355935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral tablet.
Study NCT05715138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GPi-DBS
Description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
Study NCT05715138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STN-DBS
Description: An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
Study NCT05715138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPi-DBS devices
Description: 1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).
Study NCT05715138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS devices
Description: 1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China).
Study NCT04871828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukotriene Receptor Antagonist
Description: Zafirlukast
Study NCT04871828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05355935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet.
Study NCT05238272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial random noise stimulation (tRNS)
Description: There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
Study NCT05238272 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tRNS
Description: the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
Study NCT05238272 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: the unilateral MT
Description: For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
Study NCT05238272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the unilateral MT
Description: For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
Study NCT05238272 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: the bilateral MT
Description: For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
Study NCT05238272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the bilateral MT
Description: For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
Study NCT05523557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban Training
Description: 1) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
Study NCT06066840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
Study NCT06066840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
Study NCT06178094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Training
Description: The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
Study NCT04661267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stem Cell Support Formula
Description: This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.
Study NCT04661267 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.
Study NCT06125574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
Study NCT05117983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Real-time MRI-guided neuronavigation with a Visor neuronavigation system (ANT Neuro, Enschede, Netherlands) will be used for coil positioning. Left dorsolateral prefrontal cortex target is located in each participant.
Study NCT05673330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Mobilizations
Description: 1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks